Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study by Lee, Sang Don et al.
© 2017 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean 
Children with Newly Diagnosed Idiopathic Overactive Bladder:  
a Multicenter Prospective Study
We investigated the efficacy and tolerability of solifenacin 5 mg fixed dose in children with 
newly diagnosed idiopathic overactive bladder (OAB). A total of 34 children (male/female 
patients = 16/18) aged under 13 years (mean age: 7.2 ± 2.3; range: 5–12) who were 
newly diagnosed with OAB from January 2012 to September 2014 were prospectively 
evaluated with open-label protocol. All patients were treated with solifenacin 5 mg fixed 
dose once daily for at least 4 weeks. The efficacy and tolerability of solifenacin were 
evaluated 4, 8, and 12 weeks after the initiation of treatment. The mean voiding 
frequency during daytime was decreased from 9.4 ± 3.0 to 6.5 ± 2.3 times after the 12-
week treatment (P < 0.001). The mean total OAB symptom score (OABSS) decreased from 
7.7 ± 4.2 to 3.1 ± 3.1 after the 12-week treatment (P < 0.001). The urgency and urgency 
urinary incontinence (UUI) domains significantly improved from the 12-week treatment, 
and complete resolution of urgency occurred in 38.9% of patients and the percentage of 
children with UUI among urgent patients decreased from 79.4% to 57.1%. According to 
3-day voiding diaries, the average bladder capacity increased from 90.4 ± 44.4 to 
156.2 ± 67.3 mL (P < 0.001). Drug-induced adverse effects (AEs) were reported in 7 
patients (20.6%). Our results indicate that solifenacin 5 mg fixed dose is effective against 
OAB symptoms, and its tolerability is acceptable without significant AEs in children with 
OAB.
Keywords: Anticholinergics; Child; Efficacy; Overactive Bladder; Tolerability
Sang Don Lee,1 Jae Min Chung,1,2  
Dong Il Kang,3 Dong Soo Ryu,4  
Won Yeol Cho,5 and Sungchan Park6,7
1Department of Urology, Pusan National University 
Yangsan Hospital and Research Institute for 
Convergence of Biomedical Science and Technology, 
Yangsan, Korea; 2Department of Urology, Kosin 
University College of Medicine, Busan, Korea;
3Department of Urology, Inje University Busan Paik 
Hospital, Busan, Korea; 4Department of Urology, 
Samsung Changwon Hospital, Sungkyunkwan 
University School of Medicine, Changwon, Korea;
5Department of Urology, Dong-A University Hospital, 
Dong-A University, Busan, Korea; 6Department of 
Urology, Ulsan University Hospital, Ulsan University 
College of Medicine, Ulsan, Korea; 7School of Life 
Sciences, Ulsan National Institute of Science and 
Technology, Ulsan, Korea
Received: 16 June 2016
Accepted: 16 October 2016
Address for Correspondence:
Sungchan Park, MD, PhD
Department of Urology, Ulsan University Hospital, University of 
Ulsan College of Medicine, 877 Bangeojinsunwando-ro,  
Dong-gu, Ulsan 44033, Republic of Korea
E-mail: scpark@amc.seoul.kr
https://doi.org/10.3346/jkms.2017.32.2.329 • J Korean Med Sci 2017; 32: 329-334
INTRODUCTION
Oxybutynin, tolterodine, propiverine, and solifenacin provide a 
therapeutic benefit in children with overactive bladder (OAB) 
in the clinical practice, but to our knowledge the optimal anti-
cholinergic dose is still unknown (1). In pediatric patients with 
OAB, there are extensive difficulties in initiating and managing 
clinical studies, including enrollment issues due to non-appro-
val of the solifenacin by the Food and Drug Administration in 
children, an insufficient placebo group, a lack of a regular fol-
low-up after disappearance of OAB symptoms, parental con-
sent, and others (2). Therefore, most prospective studies about 
anticholinergics medication have had failure of treatments after 
behavioral and medical therapy or presence of neurogenic blad-
der as inclusion criteria (1,3-5).
 Solifenacin is a once-daily formulation, and studies have shown 
that it significantly decreased OAB symptoms with few adverse 
effects (AEs) in adult patients with OAB (6). However, most stud-
ies on solifenacin treatment for pediatric OAB are retrospective. 
There have been only a few prospective studies on pediatric 
OAB that included mostly small numbers of patients (4,5,7). 
Until now, there have been limited data on the real use and 
benefits of solifenacin 5 mg fixed dose in pediatric patients with 
newly diagnosed idiopathic OAB. Therefore, we prospectively 
investigated the efficacy and tolerability of solifenacin 5 mg 
fixed dose in patients with newly diagnosed idiopathic OAB in 
our present study.
MATERIALS AND METHODS
Study design and patients
A total of 43 children with idiopathic OAB were evaluated from 
6 hospitals between January 2012 and September 2014, and 34 
patients who satisfied the inclusion criteria were prospectively 
enrolled. Idiopathic OAB was defined by the urgency or symp-
toms of urinary frequency (> 8 micturitions per 24 hours), with 
or without urgency urinary incontinence (UUI). Study inclusion 
criteria included no previous history of anticholinergic treatment 
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for OAB and an age between 5 and 12 years. Exclusion criteria 
included the presence of neurological anomalies, psychological 
diseases, such as attention deficiency and hyperactivity disorder 
and mental retardation, sleep disordered breathing, and con-
genital urogenital abnormalities (e.g., posterior urethral valves, 
vesicoureteral reflux, ectopic ureter, or ureterocele). Patients 
who had or were being treated for primary monosymptomatic 
nocturnal enuresis, patients with urinary tract infection (UTI), 
kidney, liver, intestine, cardiovascular system and psychologi-
cal problems, and patients with dysfunctional voiding in the 
emptying phase were also excluded from this study, as were 
patients who were allergic to anticholinergic agents or for the 
use of these drugs was contraindicated. Correctable diseases 
such as UTI and phimosis with preputial stricture were consid-
ered acceptable in our study cohort after correction.
 Children with suspected OAB completed a screening visit 
(visit 0), including a complete questionnaire to determine the 
OAB symptom score (OABSS) (8) and symptoms related to AEs, 
physical examination, urine analysis, electrocardiogram (ECG), 
kidney and bladder ultrasound 2 weeks before initial solifena-
cin medication (Fig. 1). At the enrollment visit (visit 1), the pa-
tients and their parents were taught about standard urotherapy 
and received solifenacin 5 mg after study enrollment and un-
derwent uroflowmetry with post-voiding residual urine (PVR). 
Standard urotherapy included explanation about patient’s con-
dition according to individual voiding diary, appropriate void-
ing, adequate fluid intake and avoiding the voiding postpone-
ments. PVR was checked using an ultrasound device (Bladder-
Scan® BVI 3000; Verathon, Bothell, WA, USA). We evaluated the 
questionnaire responses including current symptoms and AEs, 
physical examination findings, and the maximal bladder capac-
ity (MBC)/micturition, mean volume voided (MVV)/micturi-
tion, and mean number of voiding episodes/every 24 hours from 
3-day voiding diaries every month (visits 2–4) for three months. 
MBC and MVV were defined as biggest volume and average vol-
ume in 3-day voiding diary, respectively. Follow-up uroflowm-
etry with PVR was performed at 2 or 3 months after the begin-
ning of solifenacin medication (visit 3 or 4).
 Among the 34 children included in our study series, there were 
16 boys and 18 girls (mean age: 7.2 ± 2.3 years; range: 5–12). All 
of these children had urgency, and 27 (79.4%) had UUI. The mean 
duration of OAB symptoms before anticholinergic treatment 
was 31.2 ± 15.2 months. The OABSS total score was 7.7 ± 4.2. 
The mean urinary frequency was 9.4 ± 3.0 times per day, and 
the average bladder capacity was 90.3 ± 44.4 mL. The peak flow 
rate was 16.4 ± 8.6 mL/sec, and the PVR was within 40 mL.
 The OABSS questionnaire included frequency (score 0–2), 
nocturia (score 0–3), urgency (score 0–5), and urgency inconti-
nence (score 0–5). The OABSS total score resulted from the sum 
(score 0–15) of the scores for each item (questions 1 to 4 of Ta-
ble 1) (8). It has been proposed that the Korean version of the 
OABSS might offer clinicians a valid and reliable tool for the as-
sessment of OAB symptoms in the Korean population (9). AEs 
Table 1. Overactive bladder symptom score (OABSS) questionnaire
Question Frequency Score
1. How many times do you typically urinate from 
waking in the morning until sleeping at night?
≤ 7 
8–14
≥ 15 
0
1
2
2. How many times do you typically wake up  
to urinate from sleeping at night until waking 
in the morning? 
0
1
2
≥ 3 
0
1
2
3 
3. How often do you have a sudden desire to  
urinate, which is difficult to defer? 
Not at all
Less than once a week
Once a week or more
About once a day
2–4 times a day
5 times a day or more
0
1
2
3
4
5
4. How often do you leak urine because you  
cannot defer the sudden desire to urinate? 
Not at all
Less than once a week
Once a week or more
About once a day
2–4 times a day
5 times a day or more
0
1
2
3
4
5
Fig. 1. Study protocol.
OABSS = overactive bladder symptom score, PVR = post-voiding residual urine, AEs = adverse effects, ECG = electrocardiogram, F/U = follow-up.
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were assessed using Common Terminology Criteria for Adverse 
Events (CTCAE) version 4 (10).
Statistical analysis
All statistical analyses were two sided, with a P < 0.05 consid-
ered significant. Data were analyzed using IBM SPSS Statistics 
Version 21 (IBM Corporation, Somers, NY, USA). The Student t-
test, paired t-test, and Mann-Whitney U-test were used to com-
pare the parameters in the pre-treatment and post-treatment of 
groups. Descriptive statistics are expressed as means ± standard 
deviation. All statistical analyses were 2-sided and P < 0.05 was 
considered statistically significant.
Ethics statement
This open-label, single-group, prospective 12-week study was 
conducted in 6 institutions. The study protocol was approved 
by the Institutional Review Board of each hospital (e.g., Ulsan 
University Hospital IRB No. 2011-09-084) and by the Korean 
Food and Drug Administration. Written informed consent was 
obtained from each of the parents and patient consent was ob-
tained in all cases. Clinical data on all the patients were prospec-
tively obtained from the medical records and questionnaires.
RESULTS
The mean OABSS total score significantly decreased after 4 weeks 
of solifenacin treatment (P = 0.002). After 4, 8, and 12 weeks of 
treatment, the mean OABSS total score also gradually decreased 
from 7.7 ± 4.2 to 4.9 ± 3.1, 4.3 ± 3.7, and 3.1 ± 3.1, respectively 
(Fig. 2A). The urgency domain significantly improved from 3.0 ±  
1.8 to 1.1 ± 1.1 (P < 0.001) after the 12-week treatment, and com-
plete resolution of urgency occurred in 38.9% of patients. The 
UUI domain also significantly improved from 2.0 ± 1.7 to 0.7 ± 1.0 
(P < 0.001), and the percentage of children with UUI among ur-
gent patients decreased from 79.4% to 57.1% (Table 2). There 
were no children with re-aggravation after improvement during 
the continued 12 weeks of solifenacin treatment.
 According to the 3-day voiding diaries, the mean voiding fre-
quency during daytime significantly improved from 9.4 ± 3.0 to 
7.4 ± 2.4 (P = 0.002), 6.5 ± 2.5 and 6.5 ± 2.3 times after 4, 8, and 
12 weeks, respectively (Fig. 2B). The MVV increased from 90.4 ±  
44.4 to 156.2 ± 67.3 mL after 12 weeks of treatment (P < 0.001). 
The MBC also increased from 180.5 ± 73.4 to 206.7 ± 79.7 mL 
after 12 weeks of treatment; however, this difference was not 
statistically significant (P > 0.05).
Table 2. Treatment outcomes of solifenacin at a 5 mg fixed dose in the study cohort
Variables Visit 0 (enrollment) Visit 1 (4 weeks) Visit 2 (8 weeks) Visit 3 (12 weeks)
No. of total patients 34 31 24 19
Total OABSSs 7.7 ± 4.2 4.9 ± 3.1† 4.3 ± 3.7† 3.1 ± 3.1‡
   Urgency domain 3.0 ± 1.8 1.5 ± 1.2‡ 1.4 ± 1.3‡ 1.1 ± 1.1‡
   UUI domain 2.0 ± 1.7 1.3 ± 1.3 1.1 ± 1.3* 0.7 ± 1.0‡
3-day voiding diaries
   Frequency, episodes/day 9.4 ± 3.0 7.4 ± 2.4† 6.5 ± 2.5‡ 6.5 ± 2.3‡
   MBC, mL 180.5 ± 73.4 186.2 ± 70.2 206.4 ± 75.5 206.7 ± 79.7
   Mean voided volume, mL 90.3 ± 44.4 149.0 ± 74.6* 163.1 ± 70.0‡ 156.2 ± 67.3‡
Uroflowmetry
   Voided volume, mL 108.2 ± 82.1 - 124.5 ± 81.4
   Peak flow rate, mL/sec 16.4 ± 8.6 - 16.6 ± 8.6
   PVR, mL 14.5 ± 13.1 - 10.7 ± 9.1
OABSSs = overactive bladder symptom scores, UUI = urinary urgency incontinence, MBC = maximal bladder capacity, PVR = post-voiding residual urine. 
*P < 0.05, †P < 0.01, ‡P < 0.001 (compared to pre-treatment).
Fig. 2. Treatment outcomes. Overactive bladder symptom score (OABSS) (A) and frequency (B) had significantly improved after 12 weeks’ treatment of solifenacin (*P < 0.01; 
†P < 0.001).
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 On uroflowmetry, the maximum flow rate did not change 
(from 16.4 ± 8.6 to 16.6 ± 8.6 mL/sec) and the PVR slightly de-
creased from 14.5 to 10.7 mL, without statistical significance.
 Drug-induced AEs were reported in only 7 of these cases (20.6%) 
in our current study cohort. Dry mouth occurred in only one 
(2.9%) patient (Table 3). There were no cases of hypertension, 
hypotension, or admission to the hospital because of AEs from 
the medication.
DISCUSSION
OAB can have a major impact on health-related quality of life 
(11). The prevalence of pediatric OAB is relatively high (16.6% 
in children between 5 and 13 years of age), although it is slightly 
lower than the rate in adults in Korea (12). Therefore, many uro-
logic or pediatric doctors have adopted the use of various anti-
cholinergics, including solifenacin (13). However, there have 
been few reports regarding the efficacy of solifenacin for newly 
diagnosed idiopathic OAB in children.
 In our current study, we prospectively investigated the effica-
cy and tolerability of solifenacin (5 mg fixed dose) in Korean chil-
dren with newly diagnosed idiopathic OAB. The urgency do-
main in these cases significantly improved after the 4 weeks of 
treatment with solifenacin (P < 0.001). Moreover, the mean ur-
gency domain score gradually decreased from 3.0 ± 1.8 before 
treatment to 1.1 ± 1.1 after 12 weeks of medication. Complete 
resolution of urgency occurred in 38.9% of cases. Our study se-
ries included a high proportion of children with UUI symptoms 
among the subjects with urgency. The percentage of children 
with UUI among urgent patients decreased from 79.4% to 57.1%, 
and the UUI domain score also decreased from 2.0 ± 1.7 to 0.7 
± 1.0 after 12 weeks of medication. The efficacy of the treatment 
in our current study is difficult to compare with those of previ-
ous studies on the use of solifenacin, because inclusion criteria 
and definitions of efficacy are often heterogeneous in different 
publications. We educated parents for patients to perform the 
standard urotherapy. Standard urotherapy itself might have im-
proved OAB symptoms. Hoebeke et al. (7) retrospectively re-
ported an 85% positive response and AE frequency of 6.5% after 
treatment with solifenacin 5 mg in 138 children with oxybutynin-
resistant non-neurogenic OAB. Another small, nonrandomized, 
uncontrolled study on the combination of two anticholinergics 
including 10–30 mg oxybutynin and 4 mg tolterodine and/or 
5–10 mg solifenacin in children obtained satisfactory results (4). 
In a study of 72 children (27 with a neurogenic bladder) with 
OAB refractory to oxybutynin or tolterodine, solifenacin was an 
effective alternative to improve symptoms (5). In a recent Kore-
an retrospective study, solifenacin among various anticholiner-
gics had a 66.7% improvement rate (13).
 The long-term use of solifenacin during 5.6 months might el-
evate the improvement rate of urgency (66.7%) rather than the 
resolution rate (38.9%), as highlighted in the current study. In 
an earlier prospective randomized placebo-controlled phase 3 
clinical trial, 8 weeks of medication with propiverine yielded 
similar results to the findings of our study (2). In that report on 
171 randomized children, there was a decrease in voiding fre-
quency (−2.0 episodes for propiverine vs. −1.2 for placebo; P <  
0.001) and an improvement in incontinence episodes (−0.5 vs. 
−0.2 episodes per day; P < 0.001). Similarly, in another retrospec-
tive and observational cohort study, after administration of pro-
piverine 15.1–15.5 mg/day (n = 437) or oxybutynin 9.6–9.8 mg/
day (n = 184), continence was achieved in 61.6 vs. 58.7 % of chil-
dren with OAB of age 5–14 years (14,15). Until now, there have 
been no reports on the clinical efficacy of fesoterodine, although 
a study has been published on its pharmacokinetics, safety, and 
tolerability (16).
 In our present analysis, the MVV was increased from 90.4 ± 44.4 
to 156.2 ± 67.3 mL after a 12-week treatment (P < 0.001). MBC 
was also increased from 180.5 ± 73.4 to 206.7 ± 79.7 mL after 12 
weeks of treatment, although without statistical significance 
(P = 0.247). The MBC of 219 healthy Korean children aged 3–13 
years in a previous study was 232.7 ± 84.6 mL (range: 161–301 
mL) from 3-day voiding diaries (17). Although the symptoms 
improved in the OAB patients in our current study, the MBC af-
ter a 12-week treatment with solifenacin was still less than that 
of the healthy population. We think that OAB patients’ groups 
included the MBC of unimproved patients after treatment un-
like healthy population. Therefore, the above-mentioned retro-
spective Korean study presented results similar to those of our 
current study, as the MBC was significantly increased from 145.5 
± 66.9 to 196.8 ± 80.3 mL (13).
 Drug-induced AEs were found in only 7 of the cases (20.6%) 
in our current study. According to a previous Korean study that 
included 326 children with OAB, all AEs occurred in only 14 
(4.3%) children. Six of whom (1.8%) had interrupt to their med-
Table 3. Common Terminology Criteria for Adverse Events (CTCAE) findings in the 
study cohort
CTCAE grades 1 2 3 4 or 5
Total  
(%)
Discontinua-
tion of drug
Constipation - 1 (2.9) - - 1 (2.9) -
Diarrhea - - - - 0 -
Abdominal pain - - - - 0 -
Indigestion - - - - 0 -
Nausea - - - - 0 -
Dryness of mouth - 1 (2.9) - - 1 (2.9) -
Rhinitis - - - - 0 -
Atopy - - - - 0 -
Dizziness - - - - 0 -
Fatigue 3 (8.8) 1 (2.9) - - 4 (11.8) -
Sleepiness - 1 (2.9) - - 1 (2.9) -
Visual disturbance - - - - 0 -
Headache - - - - 0 -
Total (%) 3 (8.8) 4 (11.8) 0 0 7 (20.6) 0
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ication as a result (13). This lower AE incidence, similar to that 
(6.5%) reported in the study of Hoebeke et al. (7) may have been 
caused by the retrospective nature of the analyses, as compared 
with our current prospective study, i.e., it is possible that not all 
AEs were recorded in these earlier reports. In reality, it is unlike-
ly that patients and their parents will be queried about AEs in 
detail by the treating physicians unless it is part of a planned 
prospective study. However, the incidence of AEs in our present 
study was as still lower than that reported in adult OAB patients 
32%–47% (18-21). Moreover, the frequencies of dry mouth and 
constipation were extremely low in our current series, and arose 
in only one (2.9%) patient, respectively.
 Our study has several limitations. First, there was a significant 
drop off over the twelve weeks of the protocol. Only 19 (56%) of 
enrollees completed the protocol. Solifenacin has been not ap-
proved for children although many doctors already have used 
for pediatric OAB (13). Therefore, we respected the parents’ opin-
ion to decide whether to continue the study or not. However, 4 
of 15 enrollees who dropped off wanted to stop the protocol 
due to symptom improvement and only one stopped the study 
due to no symptom improvement. We lost follow-up of ten en-
rollees (Fig. 1). It is supposed that solifenacin had a good or no 
effect for them, or their parents just freely wanted a new drug to 
know the efficacy of solifenacin for them. Second, we could not 
check the ECG after the 12-week treatment although we did not 
use a dose titration. Therefore, we meticulously checked the 
clinical symptoms and AEs from a self-reported form and his-
tory taking simultaneously. Third, urodynamic data is missing. 
Despite these limitations, our study results contain important 
and practical information for the treatment of solifenacin 5 mg 
fixed dose in children with OAB. Solfenacin at a dose 5 mg is ef-
fective against OAB symptoms in children with an acceptable 
tolerability without significant AEs.
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